Background: Xpert MTB-Host Response (MTB-HR) has reached WHO test targets for pulmonary tuberculosis (PTB) with high bacillary loads. Our aim was to investigate the contribution of MTB-HR as a non-sputum, near point-of-care (POC) method for diagnosis of other prioritized groups, where MTB detection is more complicated, such as extrapulmonary tuberculosis (EPTB) and paucibacillary PTB.
Methods: Individuals with presumed TB disease were prospectively included in Stockholm, Sweden (n=307) and underwent MTB-HR venous and capillary testing in parallel. Clinical characterization was based on symptoms, microbiological results (microscopy, PCR and culture), radiological assessment and a panel of routine biochemical tests. ROC-analysis was performed in PTB and EPTB calculating cut-offs for maximized sensitivity and specificity including WHO targets for screening and diagnostic tests.
Findings: MTB-HR performed equally well in individuals with microbiologically confirmed PTB (AUC 0.84; 95% CI: 0.78-0.90, n=69) and EPTB (AUC 0.82 (95% CI: 0.75-0.90, n=34). Based on Youden index cut-offs the NPV was high both in microscopy- and PCR-negative PTB (-1.27, NPV 94%) and in EPTB (-1.58, NPV 95%) and fulfilled the minimum TPP sensitivity requirement for confirmed EPTB. In individuals without TB (n=204), the majority had pulmonary infectious diseases. There was a close to perfect correlation between venous and capillary samples (r= 0.97, p<0.001).
Interpretation: Capillary Xpert MTB-HR improves detection of sputum PCR-negative, culture-verified PTB and is promising as a rule-out test in EPTB. There was a strong correlation between MTB-HR score and bacterial burden. We suggest a graded MTB-HR score as more clinically relevant than a binary test result.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/infdis/jiaf110 | DOI Listing |
Zhong Nan Da Xue Xue Bao Yi Xue Ban
October 2024
Department of Prevention and Treatment, Hunan Institute for Tuberculosis Control (Hunan Chest Hospital), Changsha 410013, China.
Objectives: Reducing mortality during anti-tuberculosis treatment is crucial for completing full-course standardized therapy and achieving tuberculosis cure. The study aims to analyze the mortality and its influencing factors among pulmonary tuberculosis patients undergoing anti-tuberculosis treatment in Hunan Province.
Methods: In this retrospective cohort study, data on pulmonary tuberculosis patients from the Hunan Provincial Tuberculosis Management Information System were collected between January 1, 2019 and December 31, 2023.
Open Forum Infect Dis
March 2025
National Institutes of Health-NIAID-International Center for Excellence in Research, Chennai, India.
Background: This study investigates how (Ss) infection impacts pulmonary tuberculosis (PTB) treatment outcomes, disease severity, and bacterial burdens in PTB patients with Ss coinfection.
Methods: We used chest x-rays and sputum smear grades to assess lung conditions and bacterial loads in 483 PTB patients. Ss infection was confirmed by seropositivity, and cytokine and profibrotic factor levels were analyzed using multiplex enzyme-linked immunosorbent assay.
BMC Public Health
March 2025
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China.
Background: Tuberculosis (TB) and diabetes mellitus (DM) are known to influence each other, with insulin resistance playing a pivotal role. The relationship between the triglyceride-glucose (TyG) index and its derived indices with the incidence of TB infection across varying glucose metabolic statuses is not well defined.
Methods: This cross-sectional study utilized data from the 2011-2012 National Health and Nutrition Examination Survey.
Acta Neurol Belg
March 2025
Tropical and Communicable Diseases Research Center, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Nat Commun
March 2025
Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Lung adenocarcinoma (LUAD) radiologically displayed as subsolid nodules (SSNs) is prevalent. Nevertheless, the precise clinical management of SSNs necessitates a profound understanding of their tumorigenesis and progression. Here, we analyze 66 LUAD displayed as SSNs covering 3 histological stages including adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC) by incorporating genomics, proteomics, phosphoproteomics and glycoproteomics.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!